Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
VIPS Vipshop Holdings Ltd
CAT Caterpillar Inc
AAPL Apple Inc
ESLT Elbit Systems Ltd
AZO Autozone Inc
DITTF Daito Trust Construction Co Ltd
MYO Myomo Inc
CRVS Corvus Pharmaceuticals Inc
ARNC Arconic Corp (PITTSBURGH)
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Postmarket

Last Trade
Delayed
$144.89
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$144.89
Day's Change
0.33 (0.23%)
Bid
--
Ask
--
B/A Size
--
Day's High
145.25
Day's Low
143.01
Volume
(Above Average)
Volume:
7,947,941

10-day average volume:
7,013,269
7,947,941

UPDATE: Macy's issues Q1 sales warning, says most stores to reopen by late June

7:19 am ET May 21, 2020 (MarketWatch)
Print

Macy's Inc. (M) shares slipped 0.6% in Thursday premarket trading after the department store retailer issued a first-quarter sales warning. Macy's expects sales to total $3.00 billion to $3.03 billion, down from $5.50 billion last year and below the $3.60 billion FactSet forecast. The company also expects an operating loss of $905 million to $1.11 billion. Last year, Macy's had an operating income of $203 million. Macy's is scheduled to announce first-quarter earnings on July 1. Macy's, which has a portfolio that also includes Bloomingdale's and the Bluemercury beauty chain, closed its stores on March 18. It expects to reopen most stores by late June. Stores began to reopen on May 4 (http://www.marketwatch.com/story/macys-to-reopen-68-stores-nationwide-on-monday-2020-04-30) where allowed, and 190 total are operating with 80 expected to reopen on Memorial Day weekend. "With two weeks of results from reopened stores, customer demand is moderately higher than we anticipated," said Jeff Gennette, Macy's chief executive, in a statement. Separately, Felicia Williams, Macy's controller, with step in as interim chief financial officer, succeeding Paula Price, whose departure was previously announced. Gennette and Price will speak today at a JPMorgan investor meeting. Macy's stock has plunged more than 70% for the year to date while the S&P 500 index is down 8%.

-Tonya Garcia; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 21, 2020 07:19 ET (11:19 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.